SUPPLEMENT

Q4 2020 — Reconciliation of Non-GAAP Financial Measures

Q4 2020PDF · 6 pages189 KB
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2020 	2019 	2020 	2019
Net Earnings, after tax- as reported 	$1,738 	$4,010 	$14,714 	$15,119
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,234 	1,142 	4,660 	4,528
Litigation expense, net 	2,902 	264 	5,112 	5,096
IPR&D 	37 	- 	181 	890
Restructuring related 	85 	251 	448 	611
Acquisition and Integration related ¹ 	14 	90 	(1,073) 	319
Unrealized (gains)/losses on securities 	(373) 	(350) 	(547) 	(567)
Medical Device Regulation 2 	55 	- 	144 	-
Other 	- 	13 	6 	20
Tax Adjustments
Tax impact on special item adjustments 3 	(606) 	(123) 	(1,608) 	(1,977)
Tax legislation and other tax related 	(121) 	(270) 	(604) 	(729)
Adjusted Net Earnings, after tax 	$4,965 	$5,027 	$21,433 	$23,310
Average shares outstanding (Diluted) 	2,669.2 	2,669.1 	2,670.7 	2,684.3
Adjusted net earnings per share (Diluted) 	$1.86 	$1.88 	$8.03 	$8.68
Operational adjusted net earnings per share (Diluted) 	$1.82 	$8.00
Notes:
1
2
3
Prior year amounts have been reclassified to conform to current year disclosure
Fourth Quarter 	Twelve Months Ended
Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal of $1,148M
related to the timing of certain developmental milestones associated with the Auris Health acquisition.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously
registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and
manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The
Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-
going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical
Devices operating segments' measures of profit and loss used for making operating decisions and assessing
performance.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.

-- 1 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.4% 	16.3% 	(0.7)% 	8.3%
U.S. 	2.7% 	15.3% 	1.5% 	9.6%
International 	0.5% 	17.7% 	(2.6)% 	7.0%
WW Currency 	(0.6) 	1.7 	1.5 	1.2
U.S. 	- 	- 	- 	-
International 	(1.0) 	4.2 	2.9 	2.7
WW Operational 	2.0% 	14.6% 	(2.2)% 	7.1%
U.S. 	2.7% 	15.3% 	1.5% 	9.6%
International 	1.5% 	13.5% 	(5.5)% 	4.3%
General Surgery
Advanced Sterilization Products 	0.6 	0.2
U.S. 	0.0 	0.0
International 	1.0 	0.4
All Other Acquisitions and Divestitures 	0.1 	0.0 	0.1 	0.1
U.S. 	0.1 	(0.1) 	0.2 	0.0
International 	0.1 	0.2 	0.0 	0.1
WW Adjusted Operational 	2.1% 	14.6% 	(1.5)% 	7.3%
U.S. 	2.8% 	15.2% 	1.7% 	9.6%
International 	1.6% 	13.7% 	(4.4)% 	4.8%
Adjusted Operational Sales Growth
FOURTH QUARTER 2020 ACTUAL vs. 2019 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 2 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.1% 	8.0% 	(11.6)% 	0.6%
U.S. 	9.0% 	7.8% 	(10.9)% 	2.5%
International 	(4.6)% 	8.3% 	(12.2)% 	(1.3)%
WW Currency 	(1.9) 	(0.2) 	(0.2) 	(0.6)
U.S. 	- 	- 	- 	-
International 	(3.3) 	(0.5) 	(0.4) 	(1.1)
WW Operational 	3.0% 	8.2% 	(11.4)% 	1.2%
U.S. 	9.0% 	7.8% 	(10.9)% 	2.5%
International 	(1.3)% 	8.8% 	(11.8)% 	(0.2)%
Skin Health / Beauty
Dr. Ci Labo - Japan 	(0.1) 	0.0
U.S. 	0.0 	0.0
International 	(0.2) 	0.0
General Surgery
Advanced Sterilization Products 	0.8 	0.3
U.S. 	0.6 	0.2
International 	1.0 	0.4
Baby Care
Baby Center 	0.2 	0.0
U.S. 	0.5 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	0.0 	0.2 	0.0 	0.1
U.S. 	0.0 	0.0 	0.0 	0.0
International 	(0.1) 	0.3 	0.0 	0.1
WW Adjusted Operational 	3.1% 	8.4% 	(10.5)% 	1.5%
U.S. 	9.5% 	7.8% 	(10.2)% 	2.8%
International 	(1.5)% 	9.1% 	(10.9)% 	0.2%
Adjusted Operational Sales Growth
TWELVE MONTHS 2020 ACTUAL vs. 2019 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 3 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019
Reported Income/(Loss) Before Tax by Segment 	$ 	(2,057) 	261 	3,675 	3,030 	363 	1,208 	(334) 	(281) 	1,647 	4,218
% to Sales 	-56.9% 	7.3% 	30.0% 	28.7% 	5.5% 	18.2% 	-1.5% 	-1.4% 	7.3% 	20.3%
Intangible asset amortization expense 	109 	105 	868 	781 	257 	256 	- 	- 	1,234 	1,142
In-process research and development 	- 	- 	10 	- 	27 	- 	- 	- 	37 	-
Litigation, net 	2,762 	221 	(172) 	6 	312 	37 	- 	- 	2,902 	264
Unrealized loss/(gain) on securities 	- 	- 	(368) 	(336) 	(5) 	(14) 	- 	- 	(373) 	(350)
Restructuring related 	(1) 	62 	24 	25 	62 	164 	- 	- 	85 	251
Acquisition and integration related 	- 	- 	- 	62 	14 	28 	- 	- 	14 	90
Medical Device Regulation 	- 	- 	- 	- 	55 	- 	- 	- 	55 	-
Other 	- 	- 	- 	- 	- 	13 	- 	- 	- 	13
Adjusted Income Before Tax by Segment 	$ 	813 	649 	4,037 	3,568 	1,085 	1,692 	(334) 	(281) 	5,601 	5,628
% to Sales 	22.5% 	18.2% 	32.9% 	33.8% 	16.5% 	25.5% 	-1.5% 	-1.4% 	24.9% 	27.1%
*Estimated as of 1/26/2021.
Q4 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 4 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019
Reported Income/(Loss) Before Tax by Segment 	$ 	(1,064) 	2,061 	15,462 	8,816 	3,044 	7,286 	(945) 	(835) 	16,497 	17,328
% to Sales 	-7.6% 	14.8% 	33.9% 	20.9% 	13.3% 	28.1% 	-1.1% 	-1.0% 	20.0% 	21.1%
Intangible asset amortization expense 	415 	392 	3,246 	3,151 	999 	985 	- 	- 	4,660 	4,528
In-process research and development 	- 	- 	10 	890 	171 	- 	- 	- 	181 	890
Litigation expense, net 	3,931 	393 	834 	4,331 	347 	372 	- 	- 	5,112 	5,096
Unrealized loss/(gain) on securities 	- 	(1) 	(545) 	(572) 	(2) 	6 	- 	- 	(547) 	(567)
Restructuring related 	68 	123 	94 	93 	286 	395 	- 	- 	448 	611
Acquisition and integration related 	- 	- 	20 	185 	(1,093) 	134 	- 	- 	(1,073) 	319
Medical Device Regulation 	- 	- 	- 	- 	144 	- 	- 	- 	144 	-
Other 	- 	- 	- 	- 	6 	20 	- 	- 	6 	20
Adjusted Income Before Tax by Segment 	$ 	3,350 	2,968 	19,121 	16,894 	3,902 	9,198 	(945) 	(835) 	25,428 	28,225
% to Sales 	23.8% 	21.4% 	42.0% 	40.0% 	17.0% 	35.4% 	-1.1% 	-1.0% 	30.8% 	34.4%
*Estimated as of 1/26/2021.
Q4 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 5 of 6 --

Fourth Quarter 	Fourth Quarter
Jan. 3, 2021
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related
Medical Device
Regulation 	Other
Jan. 3, 2021
Non-GAAP
Cost of products sold 	7,814	$ 	(1,225) 	(20) 	(19) 	6,550
Selling, marketing and admin expenses 	6,457 	(7) 	6,450
Research and development expense 	4,032 	- 	(29) 	4,003
Other (Income) / Expense 	2,354 	(9) 	(2,902) 	(5) 	(14) 	373 	- 	(203)
In-process research and development 	37 	(37) 	-
Restructuring 	60 	(60) 	-
Provision for/(Benefit from) taxes on income 	(91) 	(46) 	682 	6 	16 	3 	(66) 	11 	121 	- 	636
Net Earnings 	1,738 	1,280 	2,220 	31 	69 	11 	(307) 	44 	(121) 	- 	4,965
Fourth Quarter 	Fourth Quarter
Dec. 29, 2019
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related
Medical Device
Regulation 	Other
Dec. 29, 2019
Non-GAAP
Cost of products sold 	7,134	$ 	(1,124) 	(70) 	5,940
Research and development expense 	3,232 	(47) 	3,185
Other (Income) / Expense 	16 	(18) 	(264) 	(77) 	(43) 	350 	(13) 	(49)
Restructuring 	104 	(104) 	-
Provision for taxes on income 	208 	134 	13 	37 	8 	(73) 	270 	4 	601
Net Earnings 	4,010 	1,008 	251 	214 	82 	(277) 	(270) 	9 	5,027
Twelve Months 	Twelve Months
Jan. 3, 2021
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related (1)
Medical Device
Regulation 	Other
Jan. 3, 2021
Non-GAAP
Cost of products sold 	28,427	$ 	(4,651) 	(89) 	(59) 	23,628
Selling, marketing and admin expenses 	22,084 	(17) 	22,067
Research and development expense 	12,159 	(68) 	12,091
Other (Income) / Expense 	2,899 	(9) 	(5,112) 	(112) 	1,073 	547 	(6) 	(720)
In-process research and development 	181 	(181) 	-
Restructuring 	247 	(247) 	-
Provision for taxes on income 	1,783 	504 	1,055 	36 	81 	13 	(108) 	27 	604 	- 	3,995
Net Earnings 	14,714 	4,156 	4,057 	145 	367 	(1,086) 	(439) 	117 	(604) 	6 	21,433
Twelve Months 	Twelve Months
Dec. 29, 2019
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related
Medical Device
Regulation 	Other
Dec. 29, 2019
Non-GAAP
Cost of products sold 	27,556	$ 	(4,472) 	(151) 	22,933
Research and development expense 	11,355 	(47) 	11,308
Other (Income) / Expense 	2,525 	(56) 	(5,096) 	(194) 	(272) 	567 	(20) 	(2,546)
In-process research and development 	890 	(890) 	-
Restructuring 	266 	(266) 	-
Provision for taxes on income 	2,209 	684 	1,081 	187 	100 	39 	(119) 	729 	5 	4,915
Net Earnings 	15,119 	3,844 	4,015 	703 	511 	280 	(448) 	(729) 	15 	23,310
(1) Primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition.
Prior year amounts have been reclassified to conform to current year presentation
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation and
other tax related
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation and
other tax related
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation and
other tax related
Year to Date
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation and
other tax related

-- 6 of 6 --